Visualitza per autor "Basté Rotllan, Neus"
Ara mostrant els elements 1-4 d 4
-
ICO-ICS Praxi per al tractament mèdic i amb irradiació del càncer d'orofaringe, hipofaringe, laringe i nasofaringe
Basté Rotllan, Neus; Benavente Norza, Sergio; Braña Garcia, Irene; Cirauqui-Cirauqui, Beatriz; Felip Font, Enriqueta; Lozano-Borbalas, Alicia; Marruecos-Querol, Jordi; Mesia, Ricard; Miguelsanz-García, Santiago; Taberna Sanz, Miren; Vázquez-Fernández, Silvia; Rubió-Casadevall, Jordi (Institut Català de la SalutInstitut Català d'Oncologia, 2017-11) -
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
Burtness, Barbara; Rischin, Danny; Greil, Richard; Soulières, Denis; Tahara, Makoto; de Castro Junior, Gilberto; Braña Garcia, Irene; Basté Rotllan, Neus (American Society of Clinical Oncology, 2022-07-20) -
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
Harrington, Kevin; Burtness, Barbara; Greil, Richard; Soulières, Denis; Tahara, Makoto; de Castro Junior, Gilberto; Braña Garcia, Irene; Basté Rotllan, Neus (American Society of Clinical Oncology, 2023-02-01) -
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Pai, Sara I.; Cohen, Ezra E. W.; Lin, Derrick; Fountzilas, George; Kim, Edward S.; Mehlhorn, Holger; Basté Rotllan, Neus (BMC, 2019-12-26)